Literature DB >> 21874344

Microperimetry as a routine diagnostic test in the follow-up of retinal vein occlusion?

Sibylle Winterhalter1, Anja Lux, Anna Karina Maier, Clara Scholz, Florian M A Heussen, Klaudia K Huber, Antonia M Joussen.   

Abstract

BACKGROUND: In the follow-up of retinal vein occlusions, a patient's subjective change in vision frequently cannot be confirmed by objective measurements. Furthermore, contradictory results of OCT and distance visual acuity give the impression that current routine diagnostic tests might not be satisfying for patients with retinal vein occlusions. This prospective case series analyses the value of microperimetry as a routine diagnostic test in the follow-up of patients with retinal vein occlusions during therapy.
METHODS: In a prospective case series, we tested microperimetry as a functional measure in comparison to distance visual acuity, reading ability, and OCT, on 13 patients treated for central or branch retinal vein occlusions. Treatment consisted of intravitreal bevacizumab injections combined with panretinal laser coagulation in cases of peripheral ischemia. If macular edema persisted, bevacizumab injection was repeated, or instead of this intravitreal triamcinolone or focal laser coagulation was applicated. Follow-up ranged from 6-14 months. An interim analysis was performed for the 6-month follow-up.
RESULTS: In the branch retinal vein occlusion group, the average of the retinal thickness measured by OCT was 502.22 μm (±SD 217.75 μm) at baseline and changed to 396.38 ± 154.38 at the 6-month follow-up (p = 0.121). Mean distance visual acuity stayed similar to the study entrance with 0.41 ± 0.34 at the 6-month follow-up (p = 0.944) Mean reading ability improved to 0.51 ± 0.52 at the 6-month follow-up but was not statistically significant (p = 0.435). The mean light sensitivity of microperimetry improved from baseline to the 6-month follow-up: the 40-points group improved from 8.62 ± 5.69 dB to 10.98 ± 5.42 (p = 0.060) and the 8-points group from 6.27 dB to 9.6 dB (p = 0.07) but missed statistical significance. The sector group showed in contrast to this an improvement from 6.02 ± 5.71 dB to 9 ± 6.07 dB (p = 0.025), which was statistically significant. Changes in the central vein occlusion group were not statistically significant but changes for both groups together showed statistical significance.
CONCLUSIONS: In the present case series, microperimetry was more convenient to detect, even the subtle functional changes during the disease course of branch retinal vein occlusions than distance and reading visual acuity. This indicates that microperimetry could be a possible valuable tool in the follow-up of branch retinal vein occlusions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874344     DOI: 10.1007/s00417-011-1784-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  16 in total

1.  Central visual field impairment during and following cystoid macular oedema.

Authors:  C G Kiss; T Barisani-Asenbauer; C Simader; S Maca; U Schmidt-Erfurth
Journal:  Br J Ophthalmol       Date:  2007-06-25       Impact factor: 4.638

2.  Confidence interval or p-value?: part 4 of a series on evaluation of scientific publications.

Authors:  Jean-Baptist du Prel; Gerhard Hommel; Bernd Röhrig; Maria Blettner
Journal:  Dtsch Arztebl Int       Date:  2009-05-08       Impact factor: 5.594

3.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 5.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy.

Authors:  Benjamin P Nicholson; Andrew P Schachat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-20       Impact factor: 3.117

6.  Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion.

Authors:  Fevzi Senturk; Hakan Ozdemir; Murat Karacorlu; Serra Arf Karacorlu; Omer Uysal
Journal:  Retina       Date:  2010-09       Impact factor: 4.256

7.  Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.

Authors:  Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf
Journal:  Diabetes Care       Date:  2010-11       Impact factor: 19.112

8.  Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.

Authors:  Thomas Ach; Alexandra E Hoeh; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-09       Impact factor: 3.117

9.  Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.

Authors:  T C Kreutzer; C S Alge; A H Wolf; D Kook; J Burger; R Strauss; C Kunze; C Haritoglou; A Kampik; S Priglinger
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

10.  Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.

Authors:  Katharina Kriechbaum; Franz Prager; Wolfgang Geitzenauer; Thomas Benesch; Christopher Schütze; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2009-09-10       Impact factor: 12.079

View more
  5 in total

1.  Assessment of perfused foveal microvascular density and identification of nonperfused capillaries in healthy and vasculopathic eyes.

Authors:  Alexander Pinhas; Moataz Razeen; Michael Dubow; Alexander Gan; Toco Y Chui; Nishit Shah; Mitul Mehta; Ronald C Gentile; Rishard Weitz; Joseph B Walsh; Yusufu N Sulai; Joseph Carroll; Alfredo Dubra; Richard B Rosen
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-20       Impact factor: 4.799

2.  Monthly microperimetry (MP1) measurement of macular sensitivity after dexamethasone implantation (Ozurdex) in retinal vein occlusions.

Authors:  Sibylle Winterhalter; Gerrit Alexander Vom Brocke; Matthias K Klamann; Bert Müller; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-11       Impact factor: 3.117

3.  Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy.

Authors:  Josh Wallsh; Behnam Sharareh; Ron Gallemore
Journal:  Clin Ophthalmol       Date:  2016-05-25

4.  Functional evaluation with microperimetry in large idiopathic macular holes treated by a free internal limiting membrane flap tamponade technique.

Authors:  Peirong Huang; Hong Wang; Fenge Chen; Jieqiong Chen; Yifan Hu; Junran Sun; Jingyang Feng; Hong Zhu
Journal:  BMC Ophthalmol       Date:  2020-07-23       Impact factor: 2.209

5.  Analysis of Morphologic and Functional Outcomes in Macular Edema due to Central Retinal Vein Occlusion Treated with Intravitreal Dexamethasone Implant.

Authors:  Alfredo Niro; Giancarlo Sborgia; Alessandra Sborgia; Luigi Sborgia; Claudio Furino; Nicola Recchimurzo; Giovanni Alessio
Journal:  J Ophthalmol       Date:  2018-09-09       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.